The novel coronavirus, which had initially led to pneumonia of unknown etiology in a series of patients in China\'s Hubei province in December 2019, has now precipitated a global health crisis ([@bib9]). It has been shown that SARS-CoV-2 uses the same SARS-CoV receptor ACE2 for cell entry ([@bib14]; [@bib21]; [@bib25]). This receptor is not only present in alveolar cells but also has a high expression level in other organs including kidneys ([@bib12]). Although further investigations on the prevalence of kidney injury in COVID-19 infection and the potential mechanisms of injury are needed, investigations on different cohorts of patients with COVID-19 infection have highlighted the importance of acute kidney injury (AKI) as an important complication of this infection and also a critical prognostic factor ([@bib3]). A recent meta-analysis has shown that the odds of death in patients with COVID-19 infection with AKI is more than 16 times higher than those without AKI ([@bib19]).

Prior studies on SARS-CoV have shown that the virus enters its target cells via a pH-sensitive endocytosis pathway ([@bib26]). On the grounds of preliminary findings in patients with COVID-19 suggestive of the effectiveness of treatments such as Chloroquine, which is known to cause elevation of endosomal pH and therefore disrupt virus-endosome fusion in other viral infections, it is tempting to suggest that this therapeutic strategy might be effective here as well ([@bib6]; [@bib8]; [@bib16]; [@bib21]). Furthermore, it has been shown that SARS-CoV-2 uses TMPRSS2 and CatB/L proteases for cell invasion, the latter which are blocked by elevated endosomal pH ([@bib14]).

Although the exact mechanism of kidney injury in patients with COVID-19 infection remains elusive, many potential mechanisms could be responsible for kidney damage in these patients. Cytokine storm and elevated levels of pro-inflammatory cytokines (e.g. IL-6) have been observed in patients with COVID-19 infection, particularly those in critical conditions ([@bib17]). Therefore, the inflammatory state in the kidney and increased vascular permeability might be responsible for the development of AKI. In addition, direct viral damage might be an important factor in the pathophysiology of AKI in this infection. In a postmortem histopathological examination of six patients who had developed AKI during the course of COVID-19 infection, varying degrees of acute tubular necrosis, and presence of virus-like particles in the kidneys were observed ([@bib5]). Electron microscopic examination of 26 patients with COVID-19 infection revealed coronavirus-like particles with distinctive spikes in renal podocytes and tubular epithelial cells providing further supporting evidence for direct virus invasion to the kidneys in this infection ([@bib24]). Extensive tubular vacuolization suggestive of acute tubular injury and presence of rare ill-defined round particles in the podocytes are among other histopathologic findings in this infection ([@bib1]). Kidney injury caused by direct SARS-CoV-2 invasion corroborated by postmortem histopathological studies can potentially be prevented through targeting virus-endosome fusion.

Proximal tubular cells have the highest expression of ACE2 receptors on their apical membranes and are therefore most susceptible to direct virus damage ([@bib23]; [@bib27]). Carbonic anhydrases are a group of metalloenzymes catalyzing the hydration of CO~2~ forming carbonic acid. There are two pools of carbonic anhydrase enzymes, namely carbonic anhydrase II and carbonic anhydrase IV. carbonic anhydrase II, the predominant type in the proximal tubule, is expressed in the cytoplasm while carbonic anhydrase IV is located on the plasma membrane with an extracellular active site ([@bib28]). Acetazolamide (Diamox) can inhibit both pools of carbonic anhydrases and has been shown to cause an increase in the cytosolic pH ([@bib13]; [@bib22]). Despite the fact that endosomal pH might not necessarily be identical to the intracellular pH, the alkaline cytosolic pH in these cells can possibly disrupt virus-endosome fusion and the ensuing cytopathic effects. Furthermore, the decreased intracellular H^+^ can decrease the ability of the lysosomal transporters responsible for maintaining the acidity of the lysosome ([@bib18]). This decrease in lysosomal acidity can subsequently inactivate the pH-dependent proteases which are responsible for the cleavage of viral glycoproteins enabling viral replication ([Fig. 1](#fig1){ref-type="fig"} ) ([@bib2]; [@bib23]).Fig. 1Schematic diagram depicting the potential mechanism of action of acetazolamide in the prevention of acute kidney injury in COVID-19 infection. CAII: carbonic anhydrase enzyme type 2, CAIV: carbonic anhydrase enzyme type 4, NBC1: Sodium bicarbonate cotransporter 1, NHE-3: Sodium hydrogen antiporter 3.Fig. 1

It is also notable that proximal tubular cells are proposed to be uniquely more alkaline in patients with hereditary proximal renal tubular acidosis (RTA) ([@bib15]). Although the prevalence of AKI in patients with proximal RTA who have had COVID-19 infection has not yet been studied, these patients might be more resistant to the kidney injury caused by the SARS-CoV-2 due to mechanisms we highlighted.

Although some studies have investigated the potential effectiveness of acetazolamide in other clinical settings associated with AKI through different mechanisms, the possible protective effect of this drug in AKI in patients with COVID-19 has not yet been studied ([@bib4]; [@bib7]; [@bib20]).

We, therefore, hypothesize that prophylactic administration of low dose acetazolamide in those considered to be at high risk of developing severe COVID-19 infection might exert a protective effect against kidney injury in these patients by acting through two inter-related mechanisms inhibiting virus invasion and replication. Although long term administration of acetazolamide could potentially have less proximal tubular alkalization effect once the serum bicarbonate levels have dropped, to the best of our knowledge this effect has not yet been investigated. Further experimental studies to shed light on the efficacy of this preventive strategy are needed.
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